Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance

Silo Pharma, Inc.

Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.
Exclusive global licenses from Columbia University for SPC-15 and SPC-14 (Alzheimer's).
SP-26 (ketamine implant for fibromyalgia) March 2025 data expected; 505(b)(2) pathway planned.
SPC-14 (Alzheimer's) and SPU-16 (multiple sclerosis) in preclinical with 2025 data targets.
Company states sufficient capital resources and no debt to support upcoming catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.